The CoAGulation Biomarkers and Atrial Fibrillation (COAG-AF) Pilot Study
Trial Summary
What is the purpose of this trial?
The aim of the Correlation Of CoAGulation-Atrial Fibrillation (COAG-AF) study is to prove that an increase in pro-thrombotic biomarkers in AF is associated with an increase in AF burden.Secondary objectives of the study are the following:* To investigate the impact of catheter ablation on serum pro-thrombotic biomarkers in patients with AF.* To correlate coagulation biomarkers with imaging features such as, the degree of fibrosis found on Late Gadolinium Enhancement Magnetic Resonance Imaging (LGE-MRI) scans, which is a part of standard of care.* To determine baseline values of coagulation and pro-thrombotic biomarkers in the AF population and compare those baseline values with the general population values.* To compare central and peripheral thrombotic biomarkers in patients with atrial fibrillation.
Research Team
Nassir Marrouche, MD
Principal Investigator
Tulane University
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Baseline blood draw and cardiac MRI (LGE-MRI) scan performed prior to ablation
Ablation and Immediate Post-Ablation
Catheter ablation procedure with blood samples taken during and immediately after the procedure
Follow-up
Blood draws and monitoring of atrial fibrillation burden using ECG patch at 1 month and 3 months post-ablation
Treatment Details
Find a Clinic Near You
Who Is Running the Clinical Trial?
Tulane University
Lead Sponsor